Gene · 10
Papers3,552
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,552
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Abstracts from The XXV Brazilian Diabetes Society Meeting. | Diabetol Metab Syndr | 2026 | 41913261 | PubTator, text mining | PubMed |
| ESCO2 Interacts with TRF1/2 and Facilitates Telomere Maintenance. | Int J Mol Sci | 2026 | 41898498 | PubTator, text mining | PubMed |
| Global Burden of Deep Neck Space Abscesses: Epidemiology, Challenges, and Outcomes. | J Pers Med | 2026 | 41893015 | PubTator, text mining | PubMed |
| Unraveling the Clinical and Genetic Landscape of Talipes Equinovarus (Clubfoot). | Mol Syndromol | 2026 | 41884749 | PubTator, text mining | PubMed |
| NAT2 Acetylation Phenotypes in India: A Narrative Review of Personalized TB Therapy. | Pharmgenomics Pers Med | 2026 | 41836751 | PubTator, text mining | PubMed |
| Epidemiology of drug-resistant tuberculosis in Hunan China over a 10-year period. | Front Public Health | 2026 | 41810308 | PubTator, text mining | PubMed |
| A Review on Isoniazid and Rifampicin-Associated Hepatotoxicity: From Metabolism to Immunity. | Arch Pharm (Weinheim) | 2026 | 41793109 | PubTator, text mining | PubMed |
| Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis. | Clin Infect Dis | 2026 | 41789820 | PubTator, text mining | PubMed |
| Development and Clinical Evaluation of an LC-MS/MS Method for the Determination of Isoniazid in Cerebrospinal Fluid from Tuberculous Meningitis. | Infect Drug Resist | 2026 | 41782851 | PubTator, text mining | PubMed |
| Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort. | BMJ Open | 2026 | 41775468 | PubTator, text mining | PubMed |
| Isoniazid subverting erythrocyte homeostasis: implications for tuberculosis therapy. | Front Pharmacol | 2026 | 41737554 | PubTator, text mining | PubMed |
| Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposure. | PLoS One | 2026 | 41610100 | PubTator, text mining | PubMed |
| Population pharmacokinetics of isoniazid in adult Indian tuberculosis patients: Evaluation of NAT2 polymorphisms. | Infect Genet Evol | 2026 | 41570961 | PubTator, text mining | PubMed |
| NAT10 drives hepatocellular carcinoma progression through SQLE-mediated cholesterol biosynthesis and is targetable by remodelin. | iScience | 2026 | 41550764 | PubTator, text mining | PubMed |
| Comparative evolutionary and structural bioinformatic analysis of the human N-Acetyltransferase-2 (NAT2) gene with different mammalian and avian taxa. | BMC Genomics | 2026 | 41495641 | PubTator, text mining | PubMed |
| PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature. | Clin Pharmacol Ther | 2026 | 41432551 | PubTator, text mining | PubMed |
| Arsenic and lead exposure in vietnamese gold mining communities: A case study of metabolic enzyme impacts. | Environ Toxicol Pharmacol | 2026 | 41407275 | PubTator, text mining | PubMed |
| Association between hair dye use and human cancers: A systematic review. | JAAD Int | 2026 | 41399670 | PubTator, text mining | PubMed |
| Correction: Effect of N‑acetyltransferase 2 genetic polymorphism on 4,4'‑methylenebis(2‑chloroaniline)‑induced genotoxicity and oxidative stress. | Arch Toxicol | 2026 | 41361126 | PubTator, text mining | PubMed |
| Advances in antituberculosis drug-induced liver injury: Molecular mechanisms, genetic insights, and emerging animal-free prediction models. | Toxicology | 2026 | 41314589 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10/papers?page=2